ストックスクリーナーアプリを入手
1.19
6.25%
0.07
前日終値:
$1.12
開ける：
$1.12
24時間の取引高:
7.28M
Relative Volume:
1.99
時価総額：
$264.04M
収益：
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.5613
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
+8.18%
1か月 パフォーマンス:
-16.20%
6か月 パフォーマンス:
-45.16%
1年 パフォーマンス:
-54.05%
1日の値動き範囲:
$1.11
$1.23
1週間の範囲:
$1.03
$1.23
52週間の値動き範囲:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
名前
Allogene Therapeutics Inc
セクター
電話
(650) 457-2700
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.19 | 241.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 再開されました | Oppenheimer | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-08-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
| 2021-10-20 | 開始されました | Cowen | Outperform |
| 2021-10-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-10-08 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 再開されました | Jefferies | Buy |
| 2021-05-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-01-26 | アップグレード | Stifel | Hold → Buy |
| 2020-12-10 | 再開されました | H.C. Wainwright | Buy |
| 2020-11-24 | 開始されました | BofA Securities | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-06-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-19 | アップグレード | ROTH Capital | Neutral → Buy |
| 2020-05-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | ダウングレード | SunTrust | Buy → Hold |
| 2020-04-13 | 開始されました | SunTrust | Buy |
| 2020-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-24 | 開始されました | Berenberg | Hold |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-05 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Neutral |
| 2019-05-23 | 開始されました | Stifel | Hold |
| 2019-03-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Allogene Therapeutics Inc (ALLO) 最新ニュース
Allogene Q2 Cash Tops $300 Million - AOL.com
Allogene Therapeutics Inc. Facing Inflection Point in Trend AnalysisPrice Action & Daily Entry Point Alerts - beatles.ru
Real time pattern detection on Allogene Therapeutics Inc. stockJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
Ranking Allogene Therapeutics Inc. among high performing stocks via toolsTrade Volume Summary & Weekly Top Gainers Alerts - Newser
Will Allogene Therapeutics Inc. outperform the marketJuly 2025 Spike Watch & Reliable Price Action Trade Plans - Newser
Full technical analysis of Allogene Therapeutics Inc. stockWeekly Gains Summary & Safe Capital Allocation Plans - Newser
How to track smart money flows in Allogene Therapeutics Inc.Portfolio Profit Report & Community Supported Trade Ideas - Newser
What machine learning models say about Allogene Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - Newser
Backtesting results for Allogene Therapeutics Inc. trading strategiesBreakout Watch & Advanced Swing Trade Entry Plans - Newser
What recovery options are there for Allogene Therapeutics Inc.Weekly Market Summary & Safe Capital Allocation Plans - Newser
Published on: 2025-08-19 03:10:25 - Newser
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - MSN
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript - MSN
Can swing trading help recover from Allogene Therapeutics Inc. losses2025 Macro Impact & Low Risk Entry Point Tips - Newser
Signal strength of Allogene Therapeutics Inc. stock in tech scannersJuly 2025 Chart Watch & Safe Entry Point Identification - Newser
Will Allogene Therapeutics Inc. benefit from macro trendsJuly 2025 Levels & Weekly High Momentum Picks - Newser
Allogene Therapeutics Inc. stock chart pattern explainedBuy Signal & Breakout Confirmation Trade Signals - Newser
Understanding Allogene Therapeutics Inc.’s price movementTrade Analysis Report & Verified Swing Trading Watchlist - Newser
Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges - TipRanks
Allogene Therapeutics Q2 2025 Earnings Preview: Revenue Expectations Flat, Earnings Estimates Rise - AInvest
Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - 富途牛牛
Allogene's Q2 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Allogene Therapeutics shares rise 1.92% premarket after reporting better-than-expected Q2 earnings. - AInvest
Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances - MSN
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline By Investing.com - Investing.com South Africa
Allogene Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Allogene Therapeutics Advances in CAR T Cell Therapy - TipRanks
ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest
Allogene Therapeutics Q2 2025 Earnings: A Strategic Leap in Cell Therapy Commercialization - AInvest
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Narrows Loss in Fiscal Q2 - Nasdaq
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan
Allogene Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Allogene Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Allogene Therapeutics Inc (ALLO) 財務データ
収益
当期純利益
現金流量
EPS
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):